Biomarkers, Myocardial Fibrosis and Co-Morbidities in Heart Failure With Preserved Ejection Fraction: An Overview

Archives of Medical Science - Poland
doi 10.5114/aoms.2018.76279
Full Text
Abstract

Available in full text

Categories
Medicine
Date
Authors
Publisher

Termedia Sp. z.o.o.

Related search

Interleukin-16 Promotes Cardiac Fibrosis and Myocardial Stiffening in Heart Failure With Preserved Ejection Fraction

PLoS ONE
Multidisciplinary
2013English

Treating Heart Failure With Preserved Ejection Fraction: Learning From Pulmonary Fibrosis

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2018English

September 2018 at a Glance: Co-Morbidities, Heart Failure With Preserved Ejection Fraction and Mineralocorticoid Receptor Antagonists

European Journal of Heart Failure
Cardiovascular MedicineCardiology
2018English

Biomarkers in Heart Failure With Preserved Ejection Fraction: An Update on Progress and Future Challenges

Heart Lung and Circulation
Respiratory MedicinePulmonaryCardiovascular MedicineCardiology
2020English

Biomarkers in Acutely Decompensated Heart Failure With Preserved or Reduced Ejection Fraction

American Heart Journal
Cardiovascular MedicineCardiology
2012English

Prognosis in Heart Failure With Preserved Ejection Fraction

sudan heart journal
2017English

Myocardial Injury and Cardiac Reserve Limitation in Heart Failure With Preserved Ejection Fraction

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2018English

Overview of Chinese Medicine on Heart Failure With Preserved Ejection Fraction (HFpEF)

Traditional Chinese Medicine
2016English

Diffuse Right Ventricular Fibrosis in Heart Failure With Preserved Ejection Fraction and Pulmonary Hypertension

ESC heart failure
Cardiovascular MedicineCardiology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy